Background: For patients with an increased risk of developing myopathy with statin treatment, guidelines recommend
to measure CK before and 6-12 weeks after initiating statin treatment. Further, in clinical trials of statins, the
number of patients experiencing elevated creatine kinase (CK) serum activity is commonly reported as a safety parameter.
Usually exceeding the upper limit of normal (ULN) is used as the basis of description to characterize muscular damage
potentially caused by statins. Therefore, basic data on both, proportions of patients with specific CK increases, and absolute
and relative CK increases, would be helpful to assess potential CK chances in patients. However, no such data are
available so far.
Methods: CK activity was measured in a group of blood donors (n=40) at two occasions 10 weeks apart. The 95th percentile
of absolute and relative CK increases was selected to separate true from irrelevant changes. A CK difference was defined
to be true if a random measurement error of 10% was exceeded. The numbers of subjects with true CK differences
were characterised by both measurements being under, crossing, or being above ULN, and twice ULN, respectively.
Results: Five percent of subjects (95th percentile) had an increase of CK more than 139% (men) or 120% (women), respectively,
as compared with the first measurement. Five percent of subjects had an absolute difference of at least 94 U/l
(men) and 16 U/l (women), respectively. Thirty-one percent of subjects had both CK activities below 2 times the ULN.
Six percent of them had the first measurement under and the second above ULN. In three percent, the first measurement
was under and the second above 2 times the ULN. In no subject, the first and the second measurement was above 2 times
Conclusion: It is concluded that CK serum activity substantially varies between two measurements. The present data provide
the basis for developing reference ranges of CK activity pairs by simple variables that can be useful for practitioners